Login to Your Account



New Star in Hot GLP-1 Market?

Diabetes-Obesity Deal Worth Potential $537M+ to Zealand

By Tom Wall


Friday, June 17, 2011
Copenhagen, Denmark-based Zealand Pharma A/S licensed exclusive global development and commercialization rights to its lead glucagon/GLP-1 dual agonist drug candidate ZP2929, for the treatment of patients with Type II diabetes and patients with obesity, to Boehringer Ingelheim GmbH, of Ingelheim, Germany.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription